Weight Loss Drugs

Novo Nordisk Faces Setback in Netherlands Over Wegovy Insurance Coverage
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Using Ozempic, Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery, European Medicines Agency Issues Advisory
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Pfizer Advances Once-Daily Weight-Loss Pill As It Catches Up To Tap The Lucrative Market

Weight Loss Drugs Recent News

Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
Eli Lilly's stock may rise due to supply issues at competitor Novo Nordisk, according to Reddit users. Its weight loss drug and upcoming FDA approval are also factors. Investors are optimistic about its future performance.
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market
Structure Therapeutics Obesity Candidate Is 'Very Competitive' To Eli Lilly's Orforglipron, Analyst Says
Structure Therapeutics reports positive 12-week Phase 2a obesity study results for GSBR-1290, showing a 6.2% weight loss. Cantor Fitzgerald maintains an Overweight rating with a $65 target
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks.
Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs
Goldman Sachs re-rated Eli Lilly and Novo Nordisk, citing potential for weight-loss drugs. Global sales expected to reach $130B by 2030.
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Weight loss drugs get the new parody treatment in a "South Park" streaming special.
Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars
Hims & Hers Health expands its weight loss offerings with GLP-1 injections and oral medication kits. Pricing starts at $79/month.
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market.
Eli Lilly's Weight-Loss Drug Still Going Strong, Boosts Annual Forecast
"Eli Lilly & Co's Q1 2024: Revenue hits $8.8 billion, up 26% Y/Y, driven by volume & higher prices. Strong demand for key drugs like Mounjaro & Verzenio. EPS beats at $2.58. FY24 guidance raised to $42.4 billion-$43.6 billion, citing robust performance.
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions
Eli Lilly stock is up 32% so far in 2024 and has risen 318% over three years.
Gary Black Keeping Tabs On Oprah's Upcoming TV Special About Ozempic — 'Shame, Blame And The Weight Loss Revolution'
Future Fund co-founder Gary Black shared details about Oprah Winfrey's upcoming TV special discussing her weight loss journey and the use of GLP-1 weight loss drugs, potentially impacting stocks of Novo Nordisk and Eli Lilly, major players in the market.
Oprah Winfrey To Spotlight Weight Loss Drugs In New TV Special: Will 'Shame, Blame' Come To Drug Companies — Or Could They Get Another Lift?
Weight loss drugs could get an increased spotlight with a television special from legendary TV host Oprah Winfrey.
Triple Threat Of Key Reversals: Warning Shots Fired In 3 High Fliers
In a potential warning sign to investors, three high-flying stocks had key reversals on Tuesday. This means the stocks opened to new highs before trading below their previous closing price. 
Stocks In China Flying, Lifting Sentiment In Stock Markets Across The Globe, AI And Weight Loss Drugs Get Hotter
To gain an edge, this is what you need to know today.
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
These Foods Have An Ozempic-Like Effect And Could Help You Lose Weight
GLP-1s, or weight-loss drugs like Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy, are helping millions of Americans manage their weight and diabetes.
Is Ozempic Killing Liposuction? A Stock That Could Get Hit Hard From New Weight-Loss Drugs
Ozempic, Novo Nordisk’s (NYSE: NVO) diabetes drug, is now popular for weight loss. The rise of the drug could become a major headwind for other companies that provide weight-loss services such as liposuction and bariatric surgeries.
Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results
A new survey reveals the consumer segments showing the greatest interest in weight loss medications such as Ozempic, Mounjaro, and Wegovy.
Ozempic Ingredient Gives Novo Nordisk's Kidney Trial A Positive Result: What It Means For Health Care
Novo Nordisk A/S (NYSE: NVO) shares got a boost this week after the drugmaker halted trials testing potential treatment for kidney failure on 
Pepsi Q3 Earnings Preview: Will Beverage Giant See Shares Lose More Weight In 2023?
PepsiCo (NASDAQ: PEP) is among the food and beverage stocks that could see declining sales and momentum lost from investors due to new weight loss drugs.
Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise
Food and beverage stocks endure their toughest week since May 2022, driven by concerns over weight-loss drugs and shifting consumer behavior.
Biggest Oil Drop In A Year On Biden Security Plan, Magnificent 7 Stocks Do Not Like The New Data
To gain an edge, this is what you need to know today.
FDA-Approved Weight Loss Drug Plenity's Parent Announces SPAC Deal: What Investors Should Know
A SPAC deal announced Monday could help accelerate the manufacturing of a promising weight loss drug targeting over 150 million people.